See Supplemental Patient Information
- Serious and/or life-threatening adverse events may occur when given in combination with potent CYP3A4 inhibitors. Concomitant use of these medications is contraindicated [US Black Box Warning]
- Serious toxicity such as vasospasm may occur when used concomitantly with CYP3A4 inhibitors. Consider the effects on CYP3A4 of other agents being considered for concurrent use with ergotamine
- Retroperitoneal and pleuropulmonary fibrosis have been developed in patients receiving ergotamine and caffeine therapy; there have been rare cases of fibrotic thickening of the aortic, mitral, tricuspid, and pulmonary valves with long-term continuous use of this therapy. Avoid using ergotamine SL tabs for chronic daily administration
- Chronic intoxication with ergot derivatives may produce headache, intermittent claudication, muscle pains, numbness, coldness, and pallor of the digits. If untreated, this condition may lead to gangrene. Most cases of ergotism have resulted from frank overdosage, while some were associated with apparent hypersensitivity
- Signs and symptoms of ergotism, manifested by intense arterial vasoconstriction producing signs and symptoms of peripheral vascular ischemia, may develop with long-term intermittent use of ergotamine. Exercise caution to remain within the limits of recommended dosage
- Use with sympathomimetics may cause extreme elevation of blood pressure
- Withdrawal symptoms consisting of rebound headache may occur upon discontinuation of this drug in patients who have used this medication indiscriminately over prolonged periods
Cautions: Use cautiously in
- Ergotism
- Cardiac risk factors
- Valvular heart disease
Supplemental Patient Information
- For sublingual administration only; advise patients not to crush, chew, or swallow the tablet
- Advise patients to take ergotamine SL tabs at the first sign of a migraine headache; inform them not to take more than 2 tablets for any single migraine attack
- Instruct patients not to use ergotamine SL tabs for chronic daily administration
- Advise patients to promptly report to their physician if any numbness or tingling in the fingers and toes, weakness in the legs, muscle pain in the arms and legs, chest pain or temporary speeding or slowing of the heart rate, swelling or itching develops
Pregnancy Category:X
Breastfeeding: Unsafe. Due to limited published experience with ergotamine during breastfeeding and because there is a possibility of adverse effects in the infants, it is not considered compatible for use during breastfeeding. This information is (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 11 March 2011). According to the manufacturer's data, a decision should be made for discontinuing nursing or discontinuing the drug analyzing the importance of the drug to the mother.
Pricing data from www.DrugStore.com in U.S.A.
- Ergomar 2 MG SUBL [Bottle] (ROSEDALE THERAPEUTICS)
20 mg = $170
60 mg = $489.96
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
